Danger of co-administration ferric carboxymaltose and denosumab: hypophosphatemia
Authors:
Open Access
- 27 January 2025
- journal article
- case report
- Published by Springer Nature in The Egyptian Journal of Internal Medicine
- Vol. 37 (1) , 1-4
Abstract
Both denosumab-induced hypocalcemia and ferric carboxymaltose infusion-related hypophosphatemia have been extensively documented. There are significant risks associated with combining ferric carboxymaltose parenteral infusions and denosumab, including potentially life-threatening electrolyte imbalances such as hypocalcemia and hypophosphatemia. Developing monitoring strategies for electrolyte abnormalities can be facilitated by the increased awareness of this interaction. We present the case of a 62-year-old female patient who developed severe, symptomatic hypocalcemia and hypophosphatemia despite having normal renal function. These abnormalities occurred concomitantly during treatment with denosumab for osteoporosis and ferric carboxymaltose for iron deficiency anemia.Keywords
This publication has 10 references indexed in Scilit:
- Long-term complications of permanent hypoparathyroidism in adults: prevalence and associated factorsEndocrine, 2024
- Concurrent Denosumab and Parenteral Iron Therapy Precipitating Severe Hypocalcemia and HypophosphatemiaJCEM Case Reports, 2024
- Intravenous iron: an updateInternal Medicine Journal, 2023
- Interaction between ferric carboxymaltose and denosumab causing severe hypocalcaemia and hypophosphataemia in a patient without chronic kidney diseaseInternal Medicine Journal, 2023
- Severe hypocalcaemia following denosumab and iron infusionNephrology, 2022
- Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency AnemiaJAMA, 2020
- Iron Infusion and Induced Hypophosphatemia: The Role of Fibroblast Growth Factor‐23Therapeutic Apheresis and Dialysis, 2019
- Symptomatic severe hypophosphatemia after intravenous ferric carboxymaltoseJGH Open, 2019
- Severe hypocalcaemia and hypophosphataemia following intravenous iron and denosumab: a novel drug interactionInternal Medicine Journal, 2016
- Denosumab for Prevention of Fractures in Postmenopausal Women with OsteoporosisNew England Journal of Medicine, 2009